NCT06313853 Enhancing Triadic Communication About Cognition for Older Adults With Alzheimer's Disease or Related Dementias Facing a Cancer Management Decision
| NCT ID | NCT06313853 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-04-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2024-10-01 with a primary completion date of 2027-04-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Building upon prior work, the investigator team developed a communication intervention for older adults with ADRD who are considering a decision about cancer management (adapted intervention: COACH-Cog). The investigators hypothesize that for patients with dual diagnoses of ADRD and cancer, COACH-Cog will increase autonomy support of care partners and patients in the decision-making process, leading to greater acknowledgement and support of cognitive concerns and cognitive-related goals, thereby improving goal concordant care. The investigators are conducting a pilot randomized controlled trial (RCT; cluster randomized by physician) including approximately 45 oncology clinicians and 130 patient/care partner dyads evaluating the effect of COACH-Cog on care partner and patient autonomy support, care partner well-being, goal-concordance, and communication.
Eligibility Criteria
PATIENTS: Patient Inclusion Criteria: 1. Be age 65 or older 2. Have a clinical diagnosis of Alzheimer's disease or related dementia (ADRD \[Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, or dementia of unknown subtype\]) 3. Have a clinical diagnosis of cancer (any type or stage) 4. Anticipate a potential decision about cancer-related management, as confirmed by the patient's primary medical oncology clinician. 5. Have a care partner willing and able to participate in the study 6. Are able to read and understand English. The communication coaching session will be delivered in English, thus necessitating this requirement. 7. Be able to provide informed consent (as measured by UBACC) or have a Legally Authorized Representative to provide informed consent Patient Exclusion Criteria: Patient exclusion criteria: None CARE PARTNER: Care partner inclusion criteria: 1. Age 18 or over 2. Able to read and understand spoken English 3. Able to provide informed consent Care partner exclusion criteria: None ONCOLOGY CLINICIAN: Oncology clinician inclusion criteria: 1. Oncology clinicians affiliated with the Wilmot Cancer Institute 2. Do not intend to move or retire within the next 2 years. Oncology clinician exclusion criteria: None
Contact & Investigator
Allison Magnuson
PRINCIPAL INVESTIGATOR
University of Rochester
Frequently Asked Questions
Who can join the NCT06313853 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06313853 currently recruiting?
Yes, NCT06313853 is actively recruiting participants. Contact the research team at allison_magnuson@urmc.rochester.edu for enrollment information.
Where is the NCT06313853 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06313853 clinical trial?
NCT06313853 is sponsored by University of Rochester. The principal investigator is Allison Magnuson at University of Rochester. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.